By binding to and accelerating antithrombin III, low molecular weight heparins (LMWHs) enhance the inhibition of factor Xa and thrombin. The potential advantage to using these products over standard (unfractionated) heparin is that they preferentially inhibit factor Xa; only minimally impacting thrombin and clotting times (TT or aPTT).
Enoxaparin may be useful for prophylaxis or treatment of deep vein thrombosis or pulmonary embolus. Recent pharmacokinetic work in dogs and cats, raises questions whether the drug can be effectively and practically administered long-term. In humans, it is also indicated for prevention of ischemic complications associated with unstable angina/non Q-wave MI.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
必須封閉確切依諾肝素產品、強度、濃度、容器、防腐系統、單位基準、物種、適應症、途徑、療程、腎功能、血小板、出血與處置風險、繁殖狀態、法規、監測方法與雙向交互作用。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
92%
renal